FDA anthrax tests confirmed negative
This article was originally published in The Rose Sheet
Executive Summary
Results of confirmatory testing at all FDA buildings were negative for anthrax, the agency announces Nov. 5. Centers for Disease Control & Prevention is "certain" samples initially found to be "presumptive positive" for anthrax bacteria are negative, FDA says. Agency originally revealed "preliminarily positive" anthrax findings in four agency mailrooms in Rockville, Md., as well as the CFSAN headquarters in Washington, D.C., which houses the Office of Cosmetics & Colors (1"The Rose Sheet" Nov. 5, p. 13). CDC bases confirmation for anthrax on three tests - polymerase chain reaction, gamma-phage assay and direct fluorescent antibody...
You may also be interested in...
FDA Cosmetics Office Building Tests “Presumptive Positive” For Anthrax
The Washington, D.C. building that houses FDA's Center for Food Safety & Applied Nutrition, including the Office of Cosmetics & Colors, has tested "presumptive positive" for the presence of anthrax
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.